Clear cell renal cell carcinoma (ccRCC) accounts for 80% of all kidney cancers and is characterized by loss of the VHL gene and activation of the HIF-2α factor.[1][6] HIF-2α functions as a central transcription factor that not only promotes tumor cell growth and proliferation, but also alters lipid metabolism by activating multiple signaling pathways, thereby accelerating tumor progression. HIF-2α inhibitors represent a new targeted therapeutic option for ccRCC that directly blocks this key oncogenic mechanism.[1] These inhibitors are characterized by a favorable toxic profile, which allows them to be better tolerated by patients.[1] The article discusses how HIF-2α inhibitors act through specific molecular mechanisms, particularly by modulating lipid metabolism and related molecular networks. The aim is to inform the design of future drugs and the optimization of therapeutic approaches for the clinical management of ccRCC based on existing mechanistic and clinical evidence.